Slingshot members are tracking this event:

FDA Sends Pfizer (PFE) Complete Response Letter Rejecting Oral XELJANZ Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 14, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xeljanz, Snda, Psoriasis